News 09 Apr. 2024
Curtis Announces New Partners and Counsels Across Offices in Spring 2024
more
News 25 Jan. 2024
Counsel Mohannad A. El Murtadi Suleiman Addresses “Africanization” of International Investment Law
Event 18 Aug. 2023
Partner Borzu Sabahi Speaks at FDI Moot Shenzhen
News 25 Jul. 2023
Partner Eric Gilioli Ranked in Top 10 Influential Energy & Natural Resources Lawyers in Kazakhstan in Business Today
Client Alert 28 Dec. 2023
U.S. to Impose Secondary Sanctions on Non-U.S. Banks For Financing Russia’s Defense Industry
News 28 Aug. 2024
Curtis Recognized for Excellence in Arbitration in Chambers Latin America Guide 2025
Event 22 Aug. 2023
Partner Dr. Claudia Frutos-Peterson to Speak at Arbitration and ADR Commission of the ICC Mexico
News 15 Aug. 2023
Legal Reader Publishes Article on Dr. Majed Alotaibi’s Arrival as Senior Counsel in Curtis’ Riyadh Office
News 31 Jul. 2023
Curtis Welcomes Senior Saudi Advisor, Dr. Majed Alotaibi, to its Riyadh Office
News 24 Aug. 2023
Curtis Attorneys Quoted in CoinDesk on FTX Founder Sam Bankman-Fried’s Strategy Ahead of His Criminal Trial
Client Alert 10 Jul. 2024
EU Adopts New Restrictive Measures Against Belarus
Client Alert 26 Jun. 2024
The EU Adopts its 14th Sanctions Package Against Russia
news
Curtis Attorneys Featured in IBA Insolvency and Arbitration Working Group’s New Reports
event
Fernando Tupa to Speak on Indirect Expropriation at Investment Arbitration Seminar organized by the Instituto Peruano de Arbitraje
Client Alert 13 Apr. 2020
The alert is available for download with footnotes HERE.
Overview
During the expansion of the COVID-19 virus, export restrictions have been a frequent tool adopted by governments to preserve existing stocks of medical equipment and medicines in the domestic markets. A number of the key examples of such restrictions are set out below. At the same time countries have also relaxed certain regulatory requirements and reduced import barriers for favouring the acquisition of essential goods.
Supply of Medical Products
At the beginning of the outbreak in Europe, countries such as France, Czechia and Germany (e.g. Order BAnz AR 04.03.2020 B1) halted exports of personal protective equipment (“PPE”) including gloves, masks, shields and protective clothing. In the case of Germany, exports were only admitted under “very limited conditions”. These measures contrasted with the principle of free movement of goods within the EU market as reflected in Article 35 of the Treaty of the Functioning of the European Union (“TFEU”).
The European Commission, aware that the European production of PPE was concentrated in a limited number of Member States (such as Czech Republic, France, Germany, and Poland) stepped in by mid-March. As a result, France and Germany committed removing their export restrictions (e.g. the German order was repealed on March 19). At the same time, the European Union adopted the Commission Implementing Regulation (EU) 2020/402 making the exportation of certain medical products (itemised in the regulation’s Annex 1) to third countries subject to export authorizations. The export authorizations must be processed by competent national authorities within 5 working days, but under exceptional circumstances and for duly justified reasons that period can be extended by a further period of 5 working days.
In addition to these measures, the European Union has adopted harmonized standards for medical devices to respond to urgent needs (including devices such as medical face masks, surgical curtains, gowns and suits, and washer-disinfectors for sterilisation) , and has clarified conformity assessment and market surveillance procedures within the context of the COVID-19 threat.
The United Kingdom has banned the “parallel export” of 80 crucial medicines including adrenaline, insulin, paracetamol and morphine to protect supplies during the coronavirus outbreak. The full list of medicines subject to the restrictions is available online.
The UK government describes parallel exporting as the purchase of medicines meant for UK patients but usually sold for a higher price in another country, potentially causing or aggravating supply problems.
Breaches of the ban will be considered a breach of breach of regulation 43(2) of the Human Medicines Regulations 2012 and may lead to regulatory action by the Medicines and Healthcare products Regulatory Authority (against the wholesale dealer’s licence. Specifically, sanctions can include an (i) an immediate suspension of the license or suspension of the supply of certain products under license, and (ii) a 28-day notice proposing to vary the license to restrict or prevent export activity.
On April 3, the President of the United States signed an order directing his administration to prevent crucial exports of N-95 face masks and other PPE needed in the fight against the coronavirus. The order was adopted under the Defense Production Act, and is accompanied by a memorandum vesting the authority to restrict exports on the Department of Homeland Security, the, Federal Emergency Management Agency and the Department of Health and Human Services.
In parallel, on March 6, the United States Trade Representative (“USTR”) granted relief for Chinese imports on more than 100 medical items including face masks, sanitisation products, gloves and isolation gowns. The exclusions from tariffs apply to 27 companies, on which Section 301 (of Trade Act of 1974) tariffs of 15% were originally imposed in September 2019. In addition, on March 30, the USTR invited interested parties to submit comments if they believe further modifications to Section 301 tariffs are necessary.
The Governmental Resolution No. 223 dated March 2, 2020, prohibited the export of 17 types of medical equipment, including face masks, plastic shoe covers, gloves, surgical scrubs, gas masks, protective suits, etc. The ban will remain effective until June 1, 2020.
Basic Goods and Food Supply
An increased number of countries are imposing restrictions on food exports to ensure domestic food security. As an illustration, the Russian government has limited exports of grains between the months of April and June to a quota of 7 million tonnes. In addition to this, the customs union of Russia, Kazakhstan, Belarus, Armenia and Kyrgyzstan also decided this week to restrict exports of sunflower seeds, rye and soybeans until June 30. The decision will come into force on April 12.
Other countries have adopted similar actions. Vietnam temporarily suspended new rice export contracts, while Serbia has stopped the flow of its sunflower oil and other goods. Ukraine has banned buckwheat exports until July 1 to protect local demand. Cambodia will ban rice exports to ensure local food security. Indian rice traders have stopped signing new export contracts due to labour shortages and logistics disruptions.
Compliance with International Trade Law
Under Article I of the General Agreement on Tariffs and Trade (“GATT”), Member States cannot discriminate between their trading partners (known as the “Most-Favoured-Nation” principle or “MFN”). This means that export controls should not target a particular country destination. As long as the export restrictions do not apply in a discriminatory manner the MFN shall not infringed.
At the same time GATT Article XI prohibits export restrictions other than duties, taxes or other charges, whether made effective through quotas, import or export licences or other measures. Nonetheless, GATT Article XX(b) establishes an exemption under which Member States have the right to restrict exports when those measures are necessary to protect the health of humans. Although WTO Members States receive a high level of deference for determining the level of health protection they may deem appropriate, they still have to comply with the obligation of good faith established in the chapeau of the exception. Accordingly, export restrictions shall not constitute “means of arbitrary or unjustifiable discrimination” or a “disguised restriction on international trade”.
Attorney advertising. The material contained in this Client Alert is only a general review of the subjects covered and does not constitute legal advice. No legal or business decision should be based on its contents.
Commercial Disputes - Litigation
Commercial Disputes - Arbitration
International Arbitration
Internal Investigations
White Collar Defense and Investigations
Antitrust and Competition
Cybersecurity
Intellectual Property Law
Intellectual Property Litigation
International Trade
ITC Injury Proceedings
National Security Law
Ana Amador
Associate
London
+44 20 7710 9800
New York
+1 212 696 6000
Beijing
+86 10 8564 6200
Washington, D.C.
+1 202 452 7373
Senior Associate Pablo Calderón to Speak at Greater Houston Partnership Decarbonization Event with Japanese Delegation
We use cookies on our website to enhance your browsing experience, match your interests and assess our website performance. We do not share information with any third-party for marketing purposes. Please view our privacy policy to learn more about the use of cookies on our website. By continuing to browse our website, you consent to our use of cookies.